Healius (ASX:HLS) Tariff Resilience Score: 7/10 (As of Jun. 28, 2026)


ASX:HLS Healius Ltd ASX:HLS
53 GF Score
Price A$0.37
GF Value A$1.01
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Healius Tariff Resilience Score?

Healius ASX:HLS +1.39% 53 Tariff Resilience Score is 7 as of Jun. 28, 2026. GuruFocus rates ASX:HLS with a GF Score™ of 53/100 and a GF Value™ of A$1.01 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 216 Medical Diagnostics & Research companies, Healius ranks better than 95.83% on this metric.

Healius has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Healius has Healius Ltd, a healthcare services provider, has limited direct tariff exposure. The company benefits from industry-specific exemptions and has a strong domestic market focus, reducing vulnerability.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Healius might have Highly Resilient.

Healius  (ASX:HLS) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Healius Tariff Resilience Score Related Terms

ASX:HLS vs TMO, DHR, IDXX: Tariff Resilience Score Comparison

For the Diagnostics & Research subindustry, Healius's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Healius Tariff Resilience Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Healius's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Healius's Tariff Resilience Score falls into.


ASX:HLS
53GF Score
Healius Ltd ASX:HLS
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Healius (ASX:HLS) has a Tariff Resilience Score of 7 as of Jun. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Healius ranks #9 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 4.2%.
Is Healius' Tariff Resilience Score too high?
Healius' current Tariff Resilience Score is 7. Based on the distribution chart, Healius ranks #9 out of 216 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Healius has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Healius' Tariff Resilience Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Healius ranks #9 out of 216 companies for Tariff Resilience Score. This places Healius in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Diagnostics & Research company?
A good Tariff Resilience Score depends on the Medical Diagnostics & Research industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Healius's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healius stock overvalued right now?
Based on GuruFocus' analysis, Healius (ASX:HLS) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.01, compared to a current price of A$0.37 — trading 63.9% below its estimated fair value. The current Tariff Resilience Score is 7. Healius' overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Healius (ASX:HLS), the current Tariff Resilience Score is 7 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Healius (ASX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, Healius stock appears to be undervalued. The current stock price of A$0.37 is trading 63.9% below its estimated GF Value™ of A$1.01. GuruFocus considers Healius to be Possible Value Trap.

Key valuation signals for ASX:HLS:

  • Tariff Resilience Score: 7
  • GF Value™: A$1.01 vs. price of A$0.37 (63.9% below fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the ASX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Healius Business Description

Other Exchanges PGZ:Germany
Address 161 Castlereagh Street, Level 22, Sydney, NSW, AUS, 2000
Healius is Australia's second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex.
53GF Score

Get the complete analysis for ASX:HLS

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.37
Price
A$1.01
GF Value